Sense Biodetection

The company was headquartered in Abingdon, United Kingdom, with additional operations in Cambridge, UK, and Milford, Massachusetts, USA. Sense focused on developing disposable molecular diagnostic tests that provided laboratory-quality results without the need for a reader or external power. Its proprietary Veros™ product platform utilized rapid molecular amplification technology to detect various diseases. The first product launched on this platform was the Veros™ COVID-19 test, which received a CE Mark in March 2022, allowing it to be sold in the European Union. This test could deliver PCR-quality results from a nasal swab in under 15 minutes.

The company's business model centered on providing accessible and affordable diagnostic solutions to improve patient outcomes and lower healthcare costs by enabling testing in various settings beyond traditional laboratories. Sense had secured a total of $79.2 million in funding over six rounds from investors including Koch Disruptive Technologies, Cambridge Innovation Capital, and Earlybird Health. The acquisition by Sherlock Biosciences combines Sense's hardware and chemistry with Sherlock's CRISPR-based technologies to advance the development of handheld, highly accurate tests for a range of health issues, including respiratory and sexual health.